Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations

Patent metadata

Field	Value
Publication number	US-9988418-B2
Application number	US-201414766123-A
Country	US
Kind code	B2
Filing date	Feb 5, 2014
Priority date	Feb 6, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

A method of reducing the aggregate content in a protein preparation having a target protein includes contacting the protein preparation with a thio-heterocyclic cation to form a mixture, contacting the mixture with at least one functionalized solid to remove excess thio-heterocyclic cations; and optionally contacting the mixture, simultaneously or sequentially, with at least one further functionalized solid to further reduce aggregate content of the protein preparation.

First claim

The invention claimed is:

1. A method of reducing an aggregate content in a protein preparation comprising a target protein, the method comprising:
(a) contacting the protein preparation with methylene blue to form a mixture, wherein the methylene blue is present in the mixture at a concentration range from about 0.001% to about 1% (weight/volume);
(b) contacting the mixture with at least a first functionalized solid comprising (i) negatively charged particles comprising hydrophobic groups, or (ii) a combination of negatively charged cation exchange particles and positively charged particles comprising Tris(2-aminoethyl)amine (TREN); and
(c) removing the at least first functionalized solid from the mixture, thereby providing a protein preparation substantially free of aggregates, wherein the protein preparation substantially free of aggregates comprises the target protein.

2. The method of claim 1 , wherein the protein preparation substantially free of aggregates comprises an aggregate content of 3.3% or less.

3. The method of claim 1 , comprising contacting the mixture, simultaneously or sequentially, with a second functionalized solid.

4. The method of claim 3 , wherein the at least second functionalized solid comprises positive charged particles.

5. The method claim 1 , wherein the methylene blue is present in a concentration range of from about 0.01 to about 1%, or from about 0.02 to about 0.03%.

6. The method of claim 1 , comprising, prior to (c), contacting the protein preparation or the mixture with allantoin in a concentration range selected from the group consisting of: (a) from about 0.6 to about 50%, (b) from about 1 to about 10%, and (c) from about 1 to about 2%.

7. The method of claim 1 , wherein a conductivity of the protein preparation or the mixture is within a range selected from the group consisting of: (a) from about 0.1 to about 50 mS/cm, (b) from about 1 to about 30 mS/cm, and (c) from about 5 to about 15 mS/cm.

8. The method of claim 1 , wherein an operating pH of the protein preparation or the mixture is in a range selected from the group consisting of: (a) from about 4 to about 10, (b) from about 5 to about 9, (c) from about 6 to about 8, and (d) from about 6.5 to about 7.5.

9. The method of claim 1 , wherein the mixture, prior to (c), comprises an antiviral agent selected from the group consisting of chlorhexidine, benzalkonium chloride, ethacridine, and tri(n-butyl)phosphate.

10. The method of claim 1 , wherein the mixture, prior to (c), comprises allantoin at a concentration ranging from one of the group consisting of (a) from about 0.6% to about 50%, (b) from about 0.7% to about 25%, (c) from about 0.8% to about 10%, (d) from about 0.9% to about 5%, and (e) from about 1% to about 2%.

11. The method of claim 1 , wherein the target protein comprises one selected from the group consisting of a recombinant protein, an antibody, a growth hormone, and a clotting factor.

12. The method of claim 1 , wherein the protein preparation is one selected from the group consisting of a cell-containing cell culture harvest, a substantially cell-free cell culture harvest, and a partially purified protein.

13. The method of claim 1 , wherein the at least first functionalized solid comprises a combination of negatively charged cation exchange particles and positively charged particles comprising Tris(2-aminoethyl)amine (TREN).

14. The method of claim 1 , wherein the at least first functionalized solid comprises negatively charged particles comprising hydrophobic butyl groups.

15. The method of claim 1 , comprising, after the removing, filtering the mixture.

16. A method of reducing an aggregate content in a protein preparation comprising a recombinant protein, the method comprising:
(a) contacting the protein preparation with methylene blue to a concentration of about 0.001% to about 1% (weight/volume), allantoin to a concentration of about 0.6 to about 50% (weight/volume), and a first functionalized solid comprising negatively charged hydrophobic particles;
(b) removing the at least first functionalized solid from the mixture, thereby providing a protein preparation substantially free of aggregates, wherein the protein preparation substantially free of aggregates comprises the recombinant protein.

Assignees

• Agency Science Tech & Res

Inventors

• Gagnon Peter Stanley

Classifications

• C07K1/14 Primary

  Extraction; Separation; Purification · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• B01D15/3828

  Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography · CPC title

• A61P31/12

  Antivirals · CPC title

• B01D15/327

  with hydrophobic interaction · CPC title